Wockhardt Ltd, which has become the fourth company in the world to produce recombinant human insulin, is planning to file process patents internationally to safeguard its technology.
The company is understood to have filed a process patent application in the US.
The Rs 1,100 crore company claims to have worked on the technology for over 10 years and spent around Rs 100 crore.
